Yes, adding buspirone to duloxetine is appropriate and safe for this patient with generalized anxiety disorder.
For a 63-year-old woman with GAD who tolerates duloxetine but has inadequate response, adding buspirone is a reasonable augmentation strategy with no significant drug-drug interactions or safety concerns. 1
Safety Profile
The FDA label for buspirone indicates no contraindications or warnings against combining it with duloxetine 1. The drug interaction section specifically notes that buspirone has limited interactions with most medications, and duloxetine is not listed as a problematic combination 1. Both medications work through different mechanisms—duloxetine as an SNRI and buspirone as a 5-HT1A partial agonist—which provides complementary anxiolytic effects without pharmacokinetic interference.
Evidence for Efficacy
Buspirone as Monotherapy in Elderly GAD
- Buspirone has demonstrated efficacy specifically in elderly patients with GAD at doses of 5-30 mg/day (mean 18 mg/day), with good tolerability even in patients taking multiple medications for chronic conditions 2
- A more recent study confirmed buspirone's efficacy in elderly GAD patients at 10-15 mg/day over 8 weeks 3
Duloxetine as First-Line Treatment
- Duloxetine 60-120 mg once daily is established as effective first-line treatment for GAD, with demonstrated efficacy in preventing relapse 4, 5
- A 2019 network meta-analysis ranked duloxetine among the most efficacious agents for GAD (MD -3.13) with relatively good acceptability 5
Augmentation Strategy
The most recent treatment algorithm for GAD in older adults (2024) specifically positions buspirone as a first-line alternative option, particularly when avoiding sexual side effects is a priority 6. While this algorithm doesn't explicitly address augmentation, the evidence supports:
- If duloxetine alone provides partial response: Adding buspirone is logical given its distinct mechanism and favorable side effect profile in elderly patients
- If switching is preferred: The algorithm suggests trying a different SSRI/SNRI as second-line, but augmentation with buspirone avoids losing any benefit already achieved with duloxetine 6
Important Caveats
Limited Augmentation Data
One placebo-controlled trial examined buspirone augmentation of SSRIs (citalopram/paroxetine) in treatment-refractory depression and found no significant difference from placebo augmentation (50.9% vs 46.7% response) 7. However, this study had notable limitations:
- It studied depression, not GAD
- The placebo response was unusually high
- The study was likely underpowered
- It did not specifically examine duloxetine
Practical Dosing Approach
- Start buspirone at 5 mg twice daily and titrate up to 15-30 mg/day in divided doses based on response and tolerability 1, 2
- Continue duloxetine at current dose if well-tolerated
- Allow 2-4 weeks for buspirone to demonstrate anxiolytic effects, though some benefit may appear earlier 3
- Monitor for mild side effects such as dizziness, headache, or nausea, which are typically mild to moderate 2
Special Consideration for Age
At 63 years old, this patient falls into the age range where buspirone has been specifically studied and found safe 6, 2. The combination avoids benzodiazepines, which should be used with caution in older adults 6.
One Critical Drug Interaction
Discontinue buspirone at least 48 hours before any urine catecholamine testing for pheochromocytoma, as it can cause false-positive results 1.
The combination of duloxetine plus buspirone represents a rational, evidence-based approach for this patient, with established safety and biological plausibility for enhanced efficacy through complementary mechanisms.